Fenpiverinium

In this article, we will explore Fenpiverinium from various angles and perspectives with the aim of thoroughly understanding its importance, impact and relevance in the current context. We will highlight the different facets and dimensions of Fenpiverinium, examining its influence in various fields and its interaction with other elements that shape our reality. Through a detailed and exhaustive analysis, we will reveal the complexity and depth of Fenpiverinium, offering a comprehensive vision that allows us to fully appreciate its meaning. Using a holistic approach, we will approach Fenpiverinium from a multifaceted perspective, inviting the reader to immerse themselves in a journey of discovery and understanding that broadens their horizons and enriches their knowledge on this topic.

Fenpiverinium
Clinical data
ATC code
Identifiers
  • 1-(4-Amino-4-oxo-3,3-diphenylbutyl)-1-methylpiperidinium
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H29N2O+
Molar mass337.487 g·mol−1
3D model (JSmol)
  • C1(CCCCC1)CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N
  • InChI=1S/C22H28N2O/c1-24(16-9-4-10-17-24)18-15-22(21(23)25,19-11-5-2-6-12-19)20-13-7-3-8-14-20/h2-3,5-8,11-14H,4,9-10,15-18H2,1H3,(H-,23,25)/p+1
  • Key:QDIYJDPBMZUZEH-UHFFFAOYSA-O
  (verify)

Fenpiverinium is an anticholinergic and antispasmodic compound; it is marketed as a combination drug with pitofenone hydrochloride and either nimesulide or metamizole in Eastern Europe and India to treat smooth muscle spasms and pain.

The combination with metamizole was removed from the market in Lithuania for safety reasons in 2000 and a boxed warning against use by children and adolescents was added in Serbia in 2005. In 2016 India banned marketing of the combination with nimesulide along with 344 other combination drugs; the order was overturned in December and appealed by the Government in January 2017.

References

  1. ^ "Proposed INNs List 26" (PDF). WHO Chronicle. 25 (9). 1971.. "Recommended INNs List 12" (PDF). WHO Chronicle. 26 (10). 1973.
  2. ^ Vardanyan R (2017). Piperidine-Based Drug Discovery. Elsevier. ISBN 9780128134283.
  3. ^ Consolidated List of Products - Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments, Twelfth Issue. WHO. 2005. p. 305. Archived from the original on November 8, 2014.
  4. ^ Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments, Fourteenth Issue. WHO. 2009. p. 35.[dead link]
  5. ^ "Health ministry bans 344 fixed dose combination drugs". The Times of India. March 14, 2016.
  6. ^ "Gazette of India D. L.-33004/99. PART II—Section 3—Sub-section (ii)" (PDF). Government of India. March 10, 2016. Archived from the original (PDF) on 2018-08-26. Retrieved 2017-06-22.
  7. ^ "Govt moves SC to enforce ban on 344 Fixed Dose Combination drugs". The Times of India. January 31, 2017.


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia